US 11,884,979 B2
RNA biomarkers for hereditary angioedema
Daniel J. Sexton, Melrose, MA (US); Malini Viswanathan, Acton, MA (US); Ryan Faucette, Melrose, MA (US); and Tripti Gaur, South Grafton, MA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Appl. No. 16/333,177
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
PCT Filed Sep. 15, 2017, PCT No. PCT/US2017/051772
§ 371(c)(1), (2) Date Mar. 13, 2019,
PCT Pub. No. WO2018/053260, PCT Pub. Date Mar. 22, 2018.
Claims priority of provisional application 62/395,811, filed on Sep. 16, 2016.
Prior Publication US 2019/0241961 A1, Aug. 8, 2019
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01); C12Q 1/6876 (2018.01); G01N 33/50 (2006.01); C12Q 1/6813 (2018.01); C12Q 1/6851 (2018.01); C12Q 1/686 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 1/686 (2013.01); C12Q 1/6813 (2013.01); C12Q 1/6851 (2013.01); C12Q 1/6876 (2013.01); G01N 33/502 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); G01N 2800/224 (2013.01)] 26 Claims
 
1. A method for analyzing a sample, comprising:
(i) providing a biological sample obtained from a subject having, suspected of having, or being at risk for hereditary angioedema (HAE);
(ii) measuring the level of a RNA biomarker set, wherein the RNA biomarker set comprises a messenger RNA encoding mitochondrially-encoded cytochrome C oxidase III (MT-CO3);
(iii) identifying the subject as a subject having HAE based on the level of the RNA biomarker set, an increase of the level of MT-CO3 of the subject from that of a control subject being indicative of the subject having HAE; and
(iv) administering to the subject identified as having HAE in step (iii) an effective amount of a therapeutic agent for treating HAE;
wherein the therapeutic agent is a plasma kallikrein (pKal) inhibitor, a bradykinin 2 receptor (B2R) inhibitor, and/or a Cl esterase inhibitor.